Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncoimmunology 2017-01, Vol.6 (1), p.e1132137-e1132137
Hauptverfasser:	Pitt, Jonathan M., Vétizou, Marie, Gomperts Boneca, Ivo, Lepage, Patricia, Chamaillard, Mathias, Zitvogel, Laurence
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-CTLA-4 Author's View Bacteroides cancer ipilimumab Life Sciences microbiome microbiota T cell
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!